LifePlus clinically validates first non-invasive wearable for glucose and blood pressure monitoring

LifeLeaf monitors glucose and blood pressure: ©LifePlus

LifePlus, a Silicon Valley health tech startup, announced the clinical validation of LifeLeaf, a breakthrough non-invasive, cuffless wearable device that enables continuous monitoring of blood glucose and blood pressure levels. The company says the technology offers a viable and scalable alternative to traditional methods, eliminating the need for needles, cuffs, or calibration.

The device was tested in multi-center clinical trials across four continents, including at Mayo Clinic, Cleveland Clinic Abu Dhabi, AMCR Clinic in San Diego, and Hospital Sebarang Jaya in Malaysia.

“LifeLeaf delivers clinically validated performance without the usual barriers of needles, cuffs, or cost,” said Samuel J. Asirvatham and Narayan G. Kowlgi of cardiovascular medicine at Mayo Clinic. “By making blood pressure and glucose monitoring effortless and non-invasive, it drives better patient adherence, which is crucial for managing chronic conditions like hypertension and diabetes.”

In clinical trials, LifeLeaf demonstrated a mean absolute relative difference of 10.8% versus traditional blood glucose meters and 8.5% against Dexcom G6 continuous monitors, with a 2% outlier rate—metrics comparable to current invasive options. Blood pressure monitoring showed a mean difference of –0.02 ± 12.5 mmHg for systolic and 0.03 ± 8.4 mmHg for diastolic measurements.

LifePlus says its device is 70% more cost-effective over a year than existing solutions, offering a potential leap forward in preventive care. The company is launching new global outcome studies to assess the device's ability to reduce chronic disease incidence.

Wearable tech pushes new boundaries in chronic disease management

The clinical validation of LifeLeaf marks a another step in the evolution of wearable health technology, a rapidly advancing field focused on proactive, data-driven care for chronic diseases. Traditional wearables have primarily focused on fitness and wellness, but newer devices are moving deeper into regulated medical territory—particularly in diabetes and cardiovascular care.

Continuous glucose monitoring has seen rapid growth over the last decade, but many CGMs still rely on invasive sensors and require regular calibration. LifeLeaf's approach—using non-invasive, multi-biomarker sensing powered by AI—signals a shift toward seamless, low-friction health monitoring.

Experts believe that devices like LifeLeaf could change the way diseases are detected and managed. “This kind of non-invasive monitoring is uniquely poised to improve patient adherence and enable earlier detection—two critical factors in managing chronic conditions,” said Timothy S. Bailey of AMCR Clinic and Jerome S. Fischer of MDRequest.